Effect of Citalopram on Health status, anxiety and depression in patients with chronic Obstructive pulmonary disease: a pilot study

Submission date	Recruitment status	Prospectively registered
07/08/2007	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
21/04/2008	Completed	Results
Last Edited	Condition category	[] Individual participant data
11/10/2017	Respiratory	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Christian P Subbe

Contact details

77 Brook Lane Chester United Kingdom LL13 7TD +44 (0)1978 291100 csubbe@hotmail.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Effect of Citalopram on Health status, anxiety and depression in patients with chronic Obstructive pulmonary disease: a pilot study

Acronym

ECHO

Study objectives

Chronic obstructive pulmonary disease (COPD) sufferers often experience a vicious circle of breathlessness and anxiety. These symptoms commonly lead to reduced physical activity, progressive loss of fitness, increasing social isolation and depression (which often goes undiagnosed). If this circle could be broken improved physical functioning and quality of life might result.

Ethics approval required

Old ethics approval format

Ethics approval(s)

North Wales Health Authority Research Ethics Committee, 05/02/2003

Study design

Single-centre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Chronic obstructive pulmonary disease (COPD)

Interventions

Matching oral citalopram 20 mg and placebo, starting with half a tablet once per day for two weeks, then one tablet per day for the remaining weeks with monthly follow up for three months and a two week period of half a tablet per day prior to discontinuation of treatment.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Citalopram

Primary outcome measure

Health-related quality of life, measured using St Georges Respiratory Questionnaire at baseline and 3 months

Secondary outcome measures

- 1. Depression and anxiety, measured using the Hospital Anxiety and Depression Score (HADS) at baseline and 3 months
- 2. Depression and anxiety, measured using the Depression in Medical Illness, a 10-item questionnaire (DM-10) at baseline and 3 months

Additionally at baseline, 1, 2 and 3 months a structured side effect profile was checked.

Overall study start date

01/08/2003

Completion date

01/08/2004

Eligibility

Key inclusion criteria

- 1. Diagnosis of COPD
- 2. Clinical diagnosis of anxiety or depression
- 3. Adults of either sex

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

20

Key exclusion criteria

- 1. Severe ischaemic heart disease
- 2. On treatment for anxiety or depression
- 3. Terminal illness

Date of first enrolment

01/08/2003

Date of final enrolment

01/08/2004

Locations

Countries of recruitment

United Kingdom

Wales

Study participating centre

77 Brook Lane

Chester United Kingdom LL13 7TD

Sponsor information

Organisation

North East Wales NHS Trust (UK)

Sponsor details

Wrexham Maelor Hospital Croesnewydd Road Wrexham Wales United Kingdom LL13 7TD +44 (0)1978 291100 csubbe@hotmail.com

Sponsor type

Hospital/treatment centre

Website

http://www.newalesnhstrust.org.uk/

ROR

https://ror.org/03awsb125

Funder(s)

Funder type

Government

Funder Name

North East Wales NHS Trust (UK) - Research and Development Fund

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration